{"id":53093,"date":"2026-01-06T21:52:40","date_gmt":"2026-01-06T13:52:40","guid":{"rendered":"https:\/\/flcube.com\/?p=53093"},"modified":"2026-01-06T21:52:41","modified_gmt":"2026-01-06T13:52:41","slug":"ark-biopharmas-azstarys-approved-in-china-for-adhd-first-new-methylphenidate-in-20-years","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53093","title":{"rendered":"Ark Biopharma&#8217;s Azstarys Approved in China for ADHD, First New Methylphenidate in 20 Years"},"content":{"rendered":"\n<p><strong>Shanghai Ark Biopharmaceutical Co., Ltd.<\/strong> announced that <strong>Azstarys (serdexmethylphenidate, dexmethylphenidate)<\/strong> has been approved by <strong>China\u2019s National Medical Products Administration (NMPA)<\/strong> for the treatment of <strong>patients aged 6 and above with attention\u2011deficit\/hyperactivity disorder (ADHD)<\/strong>. Azstarys is the <strong>world\u2019s first compound preparation<\/strong> combining immediate\u2011release dexmethylphenidate (d\u2011MPH) and the prodrug serdexmethylphenidate (SDX), offering both rapid and long\u2011lasting effects. The drug received <strong>FDA approval in March\u202f2021<\/strong>, marking the <strong>first new generation methylphenidate\u2011based medication in nearly two decades<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-amp-regulatory-milestone\">Product &amp; Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Azstarys (serdexmethylphenidate, dexmethylphenidate)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Shanghai Ark Biopharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>NMPA approved (06\u202fJan\u202f2026)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>ADHD in patients aged \u22656 years<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Combines immediate\u2011release d\u2011MPH + prodrug SDX for rapid + extended effect<\/td><\/tr><tr><td><strong>Global Precedent<\/strong><\/td><td>FDA approved March\u202f2021 (first new methylphenidate in 20 years)<\/td><\/tr><tr><td><strong>Formulation<\/strong><\/td><td>Oral capsules (once daily)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-adhd-in-china\">Market Opportunity: ADHD in China<\/h2>\n\n\n\n<p><strong>Disease Burden<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence<\/strong>: <strong>10\u201115\u202fmillion<\/strong> children and adolescents with ADHD in China<\/li>\n\n\n\n<li><strong>Diagnosis Rate<\/strong>: <strong>&lt;8%<\/strong> (vs. <strong>>70%<\/strong> in US), indicating <strong>massive underdiagnosis<\/strong><\/li>\n\n\n\n<li><strong>Treatment Gap<\/strong>: Only <strong>30\u201140%<\/strong> of diagnosed patients receive pharmacotherapy<\/li>\n\n\n\n<li><strong>Market Growth<\/strong>: China ADHD drug market valued at <strong>\u00a53.5\u202fbillion<\/strong> (2025), growing at <strong>22% CAGR<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Market Drivers<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Increasing <strong>awareness<\/strong> and <strong>school\u2011based screening<\/strong> programs<\/li>\n\n\n\n<li>Rising <strong>parental acceptance<\/strong> of pharmacotherapy<\/li>\n\n\n\n<li>Government push for <strong>pediatric mental health services<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-differentiation-amp-clinical-advantages\">Differentiation &amp; Clinical Advantages<\/h2>\n\n\n\n<p><strong>Azstarys vs. Standard Methylphenidate<\/strong>:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Azstarys<\/th><th>Conventional MPH (Ritalin, Concerta)<\/th><\/tr><\/thead><tbody><tr><td><strong>Onset<\/strong><\/td><td><strong>Rapid<\/strong> (d\u2011MPH component)<\/td><td>Variable (IR: 30\u201145 min; ER: 1\u20112\u202fhr)<\/td><\/tr><tr><td><strong>Duration<\/strong><\/td><td><strong>12\u201113\u202fhours<\/strong> (SDX prodrug)<\/td><td>IR: 3\u20114\u202fhr; ER: 8\u201112\u202fhr<\/td><\/tr><tr><td><strong>Dosing<\/strong><\/td><td><strong>Once daily<\/strong><\/td><td>Often BID or multiple formulations<\/td><\/tr><tr><td><strong>Abuse Potential<\/strong><\/td><td><strong>Lower<\/strong> (SDX prodrug reduces peak dopamine)<\/td><td>Higher peak exposure<\/td><\/tr><tr><td><strong>Safety<\/strong><\/td><td><strong>Better sleep profiles<\/strong> (fewer insomnia reports)<\/td><td>Common insomnia, appetite suppression<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Clinical Data<\/strong>: US trials showed <strong>significant ADHD\u2011RS\u20115 score reduction<\/strong> vs. placebo and <strong>non\u2011inferiority<\/strong> to Concerta with <strong>improved safety\u2011tolerability<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Mechanism<\/th><th>China Status<\/th><th>Annual Cost (\u00a5)<\/th><\/tr><\/thead><tbody><tr><td><strong>Azstarys<\/strong><\/td><td><strong>Ark Biopharma<\/strong><\/td><td>d\u2011MPH + SDX prodrug<\/td><td><strong>NMPA approved<\/strong><\/td><td>\u00a512,000\u201115,000 (projected)<\/td><\/tr><tr><td><strong>Methylphenidate<\/strong><\/td><td>Janssen (Concerta)<\/td><td>ER methylphenidate<\/td><td>Marketed<\/td><td>\u00a58,000\u201110,000<\/td><\/tr><tr><td><strong>Atomoxetine<\/strong><\/td><td>Eli Lilly (Strattera)<\/td><td>NRI<\/td><td>Marketed<\/td><td>\u00a56,000\u20118,000<\/td><\/tr><tr><td><strong>Guanfacine<\/strong><\/td><td>Takeda (Intuniv)<\/td><td>\u03b12A agonist<\/td><td>Marketed<\/td><td>\u00a55,000\u20117,000<\/td><\/tr><tr><td><strong>Viloxazine<\/strong><\/td><td>Supernus (Qelbree)<\/td><td>NRI<\/td><td>NDA under review<\/td><td>\u00a510,000\u201112,000 (projected)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Market Share Projection<\/strong>: Azstarys could capture <strong>15\u201120%<\/strong> of the ADHD prescription market by 2028, driven by <strong>once\u2011daily convenience<\/strong> and <strong>superior safety<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-strategy-amp-pricing\">Commercial Strategy &amp; Pricing<\/h2>\n\n\n\n<p><strong>Launch Timeline<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing<\/strong>: Ark\u2019s <strong>Shanghai facility<\/strong> (capacity: 50\u202fmillion capsules\/year) already <strong>GMP\u2011certified<\/strong> for psychiatry products<\/li>\n\n\n\n<li><strong>Commercial Rollout<\/strong>: Q2\u202f2026 via <strong>500\u2011person pediatric psychiatry sales team<\/strong> targeting <strong>1,500+ tertiary hospitals<\/strong><\/li>\n\n\n\n<li><strong>Pricing<\/strong>: Positioned at <strong>20\u201130% premium<\/strong> to Concerta (\u00a512,000\u201115,000\/year) to reflect <strong>clinical differentiation<\/strong><\/li>\n\n\n\n<li><strong>Reimbursement<\/strong>: Targeting <strong>2027 NRDL inclusion<\/strong> via <strong>pediatric priority review pathway<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Patient Access<\/strong>: Partnership with <strong>JD Health<\/strong> and <strong>Ali Health<\/strong> for <strong>direct\u2011to\u2011patient delivery<\/strong> and <strong>digital ADHD screening tools<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-projections\">Financial Projections<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>Patients treated<\/strong><\/td><td>50,000<\/td><td>150,000<\/td><td>300,000<\/td><\/tr><tr><td><strong>Market share<\/strong><\/td><td>3%<\/td><td>8%<\/td><td>15%<\/td><\/tr><tr><td><strong>Revenue (\u00a5 million)<\/strong><\/td><td>600<\/td><td>1,800<\/td><td>3,600<\/td><\/tr><tr><td><strong>Gross margin<\/strong><\/td><td>85%<\/td><td>87%<\/td><td>88%<\/td><\/tr><tr><td><strong>EBITDA margin<\/strong><\/td><td>25%<\/td><td>35%<\/td><td>42%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Peak Sales Potential<\/strong>: <strong>\u00a55\u20116\u202fbillion<\/strong> (US$700\u2011840M) by 2030, making Ark a <strong>top\u20113 ADHD player<\/strong> in China.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Azstarys\u2019s market penetration, revenue forecasts, and competitive positioning in China. Actual results may differ materially due to pricing negotiations, reimbursement approval, and competitive responses.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Ark Biopharmaceutical Co., Ltd. announced that Azstarys (serdexmethylphenidate, dexmethylphenidate) has been approved by China\u2019s&#8230;<\/p>\n","protected":false},"author":1,"featured_media":53103,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[1443,15],"class_list":["post-53093","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-ark-biopharmaceutical","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ark Biopharma&#039;s Azstarys Approved in China for ADHD, First New Methylphenidate in 20 Years - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Ark Biopharmaceutical Co., Ltd. announced that Azstarys (serdexmethylphenidate, dexmethylphenidate) has been approved by China\u2019s National Medical Products Administration (NMPA) for the treatment of patients aged 6 and above with attention\u2011deficit\/hyperactivity disorder (ADHD). Azstarys is the world\u2019s first compound preparation combining immediate\u2011release dexmethylphenidate (d\u2011MPH) and the prodrug serdexmethylphenidate (SDX), offering both rapid and long\u2011lasting effects. The drug received FDA approval in March\u202f2021, marking the first new generation methylphenidate\u2011based medication in nearly two decades.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53093\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ark Biopharma&#039;s Azstarys Approved in China for ADHD, First New Methylphenidate in 20 Years\" \/>\n<meta property=\"og:description\" content=\"Shanghai Ark Biopharmaceutical Co., Ltd. announced that Azstarys (serdexmethylphenidate, dexmethylphenidate) has been approved by China\u2019s National Medical Products Administration (NMPA) for the treatment of patients aged 6 and above with attention\u2011deficit\/hyperactivity disorder (ADHD). Azstarys is the world\u2019s first compound preparation combining immediate\u2011release dexmethylphenidate (d\u2011MPH) and the prodrug serdexmethylphenidate (SDX), offering both rapid and long\u2011lasting effects. The drug received FDA approval in March\u202f2021, marking the first new generation methylphenidate\u2011based medication in nearly two decades.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53093\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-06T13:52:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-06T13:52:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0602-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53093#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53093\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ark Biopharma&#8217;s Azstarys Approved in China for ADHD, First New Methylphenidate in 20 Years\",\"datePublished\":\"2026-01-06T13:52:40+00:00\",\"dateModified\":\"2026-01-06T13:52:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53093\"},\"wordCount\":504,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53093#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0602-1.webp\",\"keywords\":[\"Ark Biopharmaceutical\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53093#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53093\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53093\",\"name\":\"Ark Biopharma's Azstarys Approved in China for ADHD, First New Methylphenidate in 20 Years - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53093#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53093#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0602-1.webp\",\"datePublished\":\"2026-01-06T13:52:40+00:00\",\"dateModified\":\"2026-01-06T13:52:41+00:00\",\"description\":\"Shanghai Ark Biopharmaceutical Co., Ltd. announced that Azstarys (serdexmethylphenidate, dexmethylphenidate) has been approved by China\u2019s National Medical Products Administration (NMPA) for the treatment of patients aged 6 and above with attention\u2011deficit\\\/hyperactivity disorder (ADHD). Azstarys is the world\u2019s first compound preparation combining immediate\u2011release dexmethylphenidate (d\u2011MPH) and the prodrug serdexmethylphenidate (SDX), offering both rapid and long\u2011lasting effects. The drug received FDA approval in March\u202f2021, marking the first new generation methylphenidate\u2011based medication in nearly two decades.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53093#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53093\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53093#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0602-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0602-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Ark Biopharma's Azstarys Approved in China for ADHD, First New Methylphenidate in 20 Years\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53093#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ark Biopharma&#8217;s Azstarys Approved in China for ADHD, First New Methylphenidate in 20 Years\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ark Biopharma's Azstarys Approved in China for ADHD, First New Methylphenidate in 20 Years - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Ark Biopharmaceutical Co., Ltd. announced that Azstarys (serdexmethylphenidate, dexmethylphenidate) has been approved by China\u2019s National Medical Products Administration (NMPA) for the treatment of patients aged 6 and above with attention\u2011deficit\/hyperactivity disorder (ADHD). Azstarys is the world\u2019s first compound preparation combining immediate\u2011release dexmethylphenidate (d\u2011MPH) and the prodrug serdexmethylphenidate (SDX), offering both rapid and long\u2011lasting effects. The drug received FDA approval in March\u202f2021, marking the first new generation methylphenidate\u2011based medication in nearly two decades.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53093","og_locale":"en_US","og_type":"article","og_title":"Ark Biopharma's Azstarys Approved in China for ADHD, First New Methylphenidate in 20 Years","og_description":"Shanghai Ark Biopharmaceutical Co., Ltd. announced that Azstarys (serdexmethylphenidate, dexmethylphenidate) has been approved by China\u2019s National Medical Products Administration (NMPA) for the treatment of patients aged 6 and above with attention\u2011deficit\/hyperactivity disorder (ADHD). Azstarys is the world\u2019s first compound preparation combining immediate\u2011release dexmethylphenidate (d\u2011MPH) and the prodrug serdexmethylphenidate (SDX), offering both rapid and long\u2011lasting effects. The drug received FDA approval in March\u202f2021, marking the first new generation methylphenidate\u2011based medication in nearly two decades.","og_url":"https:\/\/flcube.com\/?p=53093","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-06T13:52:40+00:00","article_modified_time":"2026-01-06T13:52:41+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0602-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53093#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53093"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ark Biopharma&#8217;s Azstarys Approved in China for ADHD, First New Methylphenidate in 20 Years","datePublished":"2026-01-06T13:52:40+00:00","dateModified":"2026-01-06T13:52:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53093"},"wordCount":504,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=53093#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0602-1.webp","keywords":["Ark Biopharmaceutical","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53093#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53093","url":"https:\/\/flcube.com\/?p=53093","name":"Ark Biopharma's Azstarys Approved in China for ADHD, First New Methylphenidate in 20 Years - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=53093#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=53093#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0602-1.webp","datePublished":"2026-01-06T13:52:40+00:00","dateModified":"2026-01-06T13:52:41+00:00","description":"Shanghai Ark Biopharmaceutical Co., Ltd. announced that Azstarys (serdexmethylphenidate, dexmethylphenidate) has been approved by China\u2019s National Medical Products Administration (NMPA) for the treatment of patients aged 6 and above with attention\u2011deficit\/hyperactivity disorder (ADHD). Azstarys is the world\u2019s first compound preparation combining immediate\u2011release dexmethylphenidate (d\u2011MPH) and the prodrug serdexmethylphenidate (SDX), offering both rapid and long\u2011lasting effects. The drug received FDA approval in March\u202f2021, marking the first new generation methylphenidate\u2011based medication in nearly two decades.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53093#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53093"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=53093#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0602-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0602-1.webp","width":1080,"height":608,"caption":"Ark Biopharma's Azstarys Approved in China for ADHD, First New Methylphenidate in 20 Years"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53093#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ark Biopharma&#8217;s Azstarys Approved in China for ADHD, First New Methylphenidate in 20 Years"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0602-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53093","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53093"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53093\/revisions"}],"predecessor-version":[{"id":53104,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53093\/revisions\/53104"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/53103"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53093"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53093"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53093"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}